Seminars in Nephrology
Volume 24, Issue 5 , Pages 423-425 , September 2004

Roles of metabolic and endocrinological alterations in atherosclerosis and cardiovascular disease in renal failure: Another form of metabolic syndrome

  • Yoshiki Nishizawa

      Affiliations

    • Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Medical School, Osaka, Japan
    • Corresponding Author InformationAddress reprint requests to: Yoshiki Nishizawa, MD, PhD, Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
    • ,
  • Tetsuo Shoji

      Affiliations

    • Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Medical School, Osaka, Japan
    • ,
  • Masanori Emoto

      Affiliations

    • Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Medical School, Osaka, Japan
    • ,
  • Hideki Koyama

      Affiliations

    • Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Medical School, Osaka, Japan
    • ,
  • Hideki Tahara

      Affiliations

    • Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Medical School, Osaka, Japan
    • ,
  • Shinya Fukumoto

      Affiliations

    • Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Medical School, Osaka, Japan
    • ,
  • Masaaki Inaba

      Affiliations

    • Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Medical School, Osaka, Japan
    • ,
  • Eiji Ishimura

      Affiliations

    • Department of Nephrology, Osaka City University Medical School, Osaka, Japan
    • ,
  • Takami Miki

      Affiliations

    • Department of Geriatrics and Neurology, Osaka City University Medical School, Osaka, Japan

References 

  1. Foley RN , Parfrey PS , Sarnak MJ . Clinical epidemiology of cardiovascular disease in chronic renal disease . Am J Kidney Dis . 1998;32:S112–S119
  2. DeFronzo RA , Alvestrand A , Smith D , et al.   Insulin resistance in uremia . J Clin Invest . 1981;67:563–568
  3. Wanner C , Quaschning T . Dyslipidemia and renal disease (Pathogenesis and clinical consequences) . Curr Opin Nephrol Hypertens . 2001;10:195–201
  4. Foley RN , Parfrey PS , Harnett JD , et al.   The prognostic importance of left ventricular geometry in uremic cardiomyopathy . J Am Soc Nephrol . 1995;5:2024–2031
  5. Stenvinkel P , Heimburger O , Lindholm B , et al.   Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome) . Nephrol Dial Transplant . 2000;15:953–960
  6. Rostand SG , Drueke TB . Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure . Kidney Int . 1999;56:383–392
  7. Matthews DR , Hosker JP , Rudenski AS , et al.   Homeostasis model assessment (Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man) . Diabetologia . 1985;28:412–419
  8. Shoji T , Emoto M , Nishizawa Y . HOMA index to assess insulin resistance in renal failure patients . Nephron . 2001;89:348–349
  9. Shinohara K , Shoji T , Emoto M , et al.   Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease . J Am Soc Nephrol . 2002;13:1894–1900
  10. Wu MS , Yu CC , Yang CW , et al.   Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis . Nephrol Dial Transplant . 1997;12:2105–2110
  11. Morioka T , Emoto M , Tabata T , et al.   Glycemic control is a predictor of survival for diabetic patients on hemodialysis . Diabetes Care . 2001;24:909–913
  12. Shoji T , Nishizawa Y , Kawagishi T , et al.   Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis . Atherosclerosis . 1997;131:229–236
  13. Shoji T , Nishizawa Y , Kawagishi T , et al.   Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients . J Am Soc Nephrol . 1998;9:1277–1284
  14. Shoji T , Kawagishi T , Emoto M , et al.   Additive impacts of diabetes and renal failure on carotid atherosclerosis . Atherosclerosis . 2000;153:257–258
  15. Nishizawa Y , Shoji T , Kakiya R , et al.   Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease . Kidney Int . 2003;(suppl 84):S117–S120
  16. Degoulet P , Legrain M , Reach I , et al.   Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study . Nephron . 1982;31:103–110
  17. Koch M , Kutkuhn B , Trenkwalder E , et al.   Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients . J Am Soc Nephrol . 1997;8:1889–1898
  18. Wanner C , Krane V , Ruf G , et al.   Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators . Kidney Int . 1999;71:S222–S226 suppl
  19. Zager PG , Nikolic J , Brown RH , et al.   “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc . Kidney Int . 1998;54:561–569
  20. Foley RN , Herzog CA , Collins AJ . Blood pressure and long-term mortality in United States hemodialysis patients (USRDS waves 3 and 4 study) . Kidney Int . 2002;62:1784–1790
  21. Koyama H , Tabata T , Nishizawa Y , et al.   Plasma endothelin levels in patients with uraemia . Lancet . 1989;1:991–992
  22. Park CW , Oh YS , Shin YS , et al.   Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism . Am J Kidney Dis . 1999;33:73–81
  23. Lemmila S , Saha H , Virtanen V , et al.   Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis . Am J Nephrol . 1998;18:404–410
  24. Tabata T , Suzuki R , Kikunami K , et al.   The effect of 1 alpha-hydroxyvitamin D3 on cell-mediated immunity in hemodialyzed patients . J Clin Endocrinol Metab . 1986;63:1218–1221
  25. Tabata T , Shoji T , Kikunami K , et al.   In vivo effect of 1 alpha-hydroxyvitamin D3 on interleukin-2 production in hemodialysis patients . Nephron . 1988;50:295–298
  26. Suematsu Y , Nishizawa Y , Shioi A , et al.   Effect of 1,25-dihydroxyvitamin D3 on induction of scavenger receptor and differentiation of 12-O-tetradecanoylphorbol-13-acetate-treated THP-1 human monocyte like cells . J Cell Physiol . 1995;165:547–555
  27. Shoji T , Shinohara K , Kimoto E , et al.   Lower risk for cardiovascular mortality in oral vitamin D3 users in hemodialysis population . Nephrol Dial Transplant . 2004;19:179–184
  28. Teng M , Wolf M , Lowrie E , et al.   Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy . N Engl J Med . 2003;349:446–456
  29. Block GA , Hulbert-Shearon TE , Levin NW , et al.   Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients (A national study) . Am J Kidney Dis . 1998;31:607–617
  30. Ganesh SK , Stack AG , Levin NW , et al.   Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients . J Am Soc Nephrol . 2001;12:2131–2138
  31. Kawagishi T , Nishizawa Y , Konishi T , et al.   High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia . Kidney Int . 1995;48:820–826
  32. Chertow GM . Slowing the progression of vascular calcification in hemodialysis . J Am Soc Nephrol . 2003;14:S310–S314

PII: S0270-9295(04)00102-0

doi: 10.1016/j.semnephrol.2004.06.018

Seminars in Nephrology
Volume 24, Issue 5 , Pages 423-425 , September 2004

Article Tools